6 terminated. 6 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 6 |
| Phase 2 | 3 | Terminated 3 |
Follow Sars-CoV2: new trials by email Literature Review of Sars-CoV2 trials Research Report on Sars-CoV2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Linagliptin 5 MG - COVID 19, Coronavirus | Phase 3 | Terminated | Rabin Medical Center | 64 | 2020-10-01 | 2021-06-02 |
| Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients BIO101, Placebo - Covid-19, SARS-CoV2 | Phase 2 / Phase 3 | Terminated | Biophytis | 238 | 2020-08-26 | 2026-08-12 |
| Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19 Janus Kinase Inhibitor (ruxolitinib), Placebo - Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2 | Phase 2 / Phase 3 | Terminated | Vanderson Geraldo Rocha | 5 | 2020-08-14 | 2021-04-08 |
| Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19 Hyperbaric oxygen - SARS (Severe Acute Respiratory Syndrome), Cytokine Storm | Phase 2 / Phase 3 | Terminated | Karolinska Institutet | 34 | 2020-06-03 | 2023-01-09 |
| Preventing COVID-19 Complications With Low- and High-dose Anticoagulation Enoxaparin - COVID, Sars-CoV2 | Phase 3 | Terminated | University Hospital, Geneva | 160 | 2020-04-28 | 2021-09-14 |
| Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients Hydroxychloroquine (HCQ) - Sars-CoV2 | Phase 3 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 7 | 2020-04-03 | 2020-09-07 |
COVID-19 (4) · Coronavirus Infections (1) · Cytokine Release Syndrome (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Respiratory Distress Syndrome (1) · Respiratory Tract Diseases (1) · Severe Acute Respiratory Syndrome (1) · Thrombosis (1)
Coronaviridae Infections (4) · Infections (4) · Lung Diseases (4) · Nidovirales Infections (4) · Pneumonia (4) · Pneumonia, Viral (4) · RNA Virus Infections (4) · Respiratory Tract Infections (4) · Virus Diseases (4) · Coronavirus Infections (3) · Respiratory Tract Diseases (3) · Cardiovascular Diseases (1) · Embolism and Thrombosis (1) · Inflammation (1) · Nutritional and Metabolic Diseases (1)
Enoxaparin (1) · Heparin (1) · Hydroxychloroquine (1) · Hyperbaric Oxygenation (1) · Janus Kinase Inhibitors (1) · Linagliptin (1) · ruxolitinib (1)
Biophytis (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Karolinska Institutet (1) · Rabin Medical Center (1) · University Hospital, Geneva (1) · Vanderson Geraldo Rocha (1)
Brazil (2) · France (2) · Belgium (1) · Germany (1) · Israel (1) · Puerto Rico (1) · Sweden (1) · Switzerland (1) · United States (1)
Anders Kjellberg, MD (1) · Capucine Morelot-Panzini, MD (1) · Kenny Rodriguez-Wallberg, MD, PhD (1) · Peter Lindholm, MD, PhD (1)
PMID 32407672, PMID 33430924, PMID 33502773, PMID 34226219, PMID 35002970, PMID 35244208, PMID 37510965, PMID 38545090, PMID 39393522